UN Meeting Opens On Impact Of Science And Technology On Humanity 15/05/2018 by Damilola Adepeju for Intellectual Property Watch 1 Comment A United Nations meeting gathering ministers, high-level representatives, scientists and technology experts opened yesterday with a discussion of the impacts that rapid innovative trends in science and technology have on development, the UN Sustainable Development Goals (SDGs), and humanity itself.
Trump Declares Intent To Stop Pharma Companies From ‘Gaming’ Patent System 11/05/2018 by William New, Intellectual Property Watch 2 Comments US President Trump today declared in a White House speech his intent to “take steps” to lower drug prices by stopping “gaming of regulatory and patent processes by drug makers to unfairly protect monopolies,” as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as “freeloading” on US innovation by foreign governments, and addressing “unfair” intellectual property and market access policies in trade agreements.
Brazilian Superior Court Of Justice Stops Patent Term Extension Attempts 11/05/2018 by Intellectual Property Watch 4 Comments Pedro Marcos Nunes Barbosa writes: In April 2018, the Brazilian Superior Court of Justice (STJ) ruled on a controversial patent term extension scheme, for the third time since Brazil adopted TRIPS compliant legislation in 1996. The first ruling on this topic, upheld by the STJ, was decided, unanimously, in the year 2009 (docket REsp 960.728, Justice Andrighi). In that case, a famous agrochemical multinational company sought an exotic interpretation of the impacts brought by the minimum deadline granted to a patent, since the WTO’s annex treaty imposed the uniform extension of 20 years. In other words, although the agrochemical company had obtained its exclusivity right in a pre-TRIPS context (where Brazilian Law guaranteed a 15 years property right), but unsatisfied, after the Agreement was implemented, the plaintiff requested a judicial pass for a five year extra period of competition absence.
Study Finds Rise In Use Of India’s Section 3(d) Against Pharma Primary Patents 11/05/2018 by Adithi Koushik for Intellectual Property Watch 2 Comments Access to affordable medicines is one of the most pressing policy issues globally. India has played a prominent role as “pharmacy of the developing world” with its generic medicine industry; however, the interpretation and implementation of a particular section of the law can significantly affect this role, according to a recent study.
UNCTAD To Look At Rapid Technological Change And Developing Countries 10/05/2018 by Intellectual Property Watch 2 Comments Ministers, leading scientists and innovators will gather next week at the United Nations in Geneva to discuss rapid technological change and developing countries.
Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 by Catherine Saez, Intellectual Property Watch 14 Comments Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries, civil society organised itself to increase access to sofosbuvir for millions in need.
US To Weaken Post-Grant Patent Reviews 09/05/2018 by Steven Seidenberg for Intellectual Property Watch 1 Comment Government agencies do not ordinarily relinquish power easily, or without a struggle. But these are not ordinary times in the USA. Trump appointees have pushed a variety of federal agencies – including Interior, EPA, and HUD – to surrender much of their powers. Yesterday, the USPTO joined that list, when it announced proposed new regulations that would weaken the agency’s review of existing patents.
Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 by Catherine Saez, Intellectual Property Watch 15 Comments The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled.
What You Can Learn From The Licensing Execs At The LESI Annual Conference 2018 08/05/2018 by Guest contributor for Intellectual Property Watch Leave a Comment “Strong IP Drives the Bottom Line”: Licensing executives, technology transfer officers and attorneys from all over the world met under this theme at the annual conference of the Licensing Executives Society International (LESI) in San Diego from April 30 to May 1, 2018. Each year, the LESI annual conference brings together the strategists, pioneers and deal makers of the world to exchange about the hot topics in licensing, technology transfer and the business of IP. Bastian July of GoodIP reports on what you can learn from the keynote speeches and workshops he attended.
US State-By-State Analysis Shows Benefits Of Funding Global Health Research 07/05/2018 by Intellectual Property Watch 2 Comments In the current atmosphere in the United States of funding cuts for global health threats like malaria and HIV/AIDS by the Trump Administration, a new state-by-state analysis claims to show its profound implications for research and jobs across the country.